Xingyu Chen | Cancer Biology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Xingyu Chen | Cancer Biology | Young Scientist Award

Research Bioinformatician | Cedars-Sinai Medical Center | United States

Dr. Xingyu Chen is a research bioinformatician and computational oncologist specializing in sex chromosome genomics, cancer immunology, and precision medicine. His work has revealed the Loss of the Y Chromosome (LOY) as a causal driver of cancer immune evasion in men, demonstrating its role in tumor progression, immune dysfunction, and therapy resistance. He pioneered the development of the world’s first Sex Chromosome-Aware Genomic Large Language Model, integrating AI with genomic data to enhance cancer diagnostics and guide precision therapies. His research combines multi-omics analysis, single-cell and spatial transcriptomics, and deep-learning models to uncover mechanisms of tumor evolution, T-cell exhaustion, and sex-specific cancer vulnerabilities. Chen has contributed to high-impact publications in journals such as Nature, Oncogene, and International Journal of Molecular Sciences, with 800 citations, an h-index of 15, and multiple first/co-first author contributions, reflecting his influence in the field. His work extends to translational applications, including LOY-informed cellular therapies and radiogenomic predictive algorithms for bladder cancer, leading to patentable innovations. He has also mentored trainees, co-supervised projects, and collaborated with international institutions to advance integrative cancer genomics and AI-driven therapeutics. Overall, his research advances the understanding of male-biased cancer mechanisms and supports the development of innovative diagnostic and therapeutic strategies, bridging fundamental biology, computational modeling, and clinical applications to improve outcomes for men with cancer.

Featured Publications

Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., … et al. (2023). Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature, 619(7970), 624–631.

Jin, Y., Wang, Z., He, D., Zhu, Y., Chen, X., & Cao, K. (2021). Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma. Cancer Medicine, 10(23), 8693–8707.

Ayesha Ahmed | Cancer Biology | Research Excellence Award

Published on by Young Scientists Awards

Ms. Ayesha Ahmed | Cancer Biology | Research Excellence Award

Roosevelt University | United States

Ms. Ayesha Ahmed is an emerging pharmacist and pharmaceutical sciences researcher with a strong interdisciplinary foundation spanning clinical practice, pharmaceutical manufacturing, research coordination, and academic support. Her academic and professional journey reflects a commitment to advancing global healthcare through evidence-based practice, scientific inquiry, and collaborative learning. She has contributed to research projects that integrate stakeholder engagement, strategic planning, and analytical evaluation, enabling the development of targeted research approaches within the pharmaceutical and healthcare sectors. Her scientific interests encompass drug formulation, regulatory science, clinical pharmacy, and translational research aimed at improving therapeutic outcomes. She has co-authored publications exploring corrosion-resistant polymer modifications for industrial applications, barriers and enablers influencing community pharmacists’ participation in deprescribing initiatives, and molecular insights into CRP interactomes related to cellular signaling and tumorigenicity. These works demonstrate her ability to engage with both laboratory-based and clinical-conceptual research, bridging basic science with healthcare practice. She possesses strong communication and instructional skills refined through academic tutoring roles, where she supported learners in developing scientific writing, analytical reasoning, and pharmacy-related competencies. Her international training exposure has strengthened her understanding of pharmaceutical manufacturing processes, regulatory frameworks, and quality-assurance practices within diverse healthcare systems. Motivated by a passion for patient-centered care, interdisciplinary research, and global health development, she continues to expand her expertise through advanced study in pharmaceutical sciences. She aims to contribute to innovations in drug development, clinical decision-making, and pharmacy practice through research that supports safety, effectiveness, and equitable access to healthcare.

Featured Publication

Gerhardt, A., Nanakaliy, D., Shah, H. D., Sarfaraz, S., Madigan, C., Downing, M., Elliott, R. P., Dipto, R., Vrapciu, B., Noetzel, J. W., et al. (2025). Evaluating the CRP interactome: Insights into possible novel roles in cellular signaling and tumorigenicity. Current Issues in Molecular Biology, 47(12), Article 1003.

Elshazly, M., Wilkinson, J., Jawad, S., Ahmed, A., ElGeed, H., & Yusuff, K. B. (2025). Enablers and barriers to community pharmacists’ readiness to implement deprescribing of inappropriate medications for older adults in Qatar. PLOS ONE, 20(1), Article e0316363.

Maonan Wang | Tumor metabolism | Best Researcher Award

Published on by Young Scientists Awards

Dr. Maonan Wang | Tumor metabolism | Best Researcher Award

Assistant Professor | Central south university, China

Maonan Wang is an Assistant Professor at the Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, China. He holds a Ph.D. from Southeast University and completed a Joint-Ph.D. at the National University of Singapore. His research focuses on nanomedicine, tumor immunotherapy, and biomaterials for cancer treatment. Wang has published extensively in high-impact journals, contributing to advances in cancer diagnostics and therapeutics. His work involves innovative nano-delivery systems and biosynthesized nanomaterials. He has received multiple research accolades and actively collaborates on interdisciplinary biomedical projects.

Profile

Scopus

🎓 Education

Ph.D., Southeast University (2018-2022). Joint-Ph.D., National University of Singapore, Chemical and Biomolecular Engineering (2021-2022). M.D., Central South University (2015-2018). B.D., Changzhi Medical College (2011-2015). Currently serving as an Assistant Professor at Central South University since August 2022.

💼 Experience

Assistant Professor, Central South University (2022-Present). Researcher, National University of Singapore (2021-2022). Ph.D. Researcher, Southeast University (2018-2022). Extensive experience in nanomedicine, cancer therapy, and biomaterials research. Collaborated on multiple interdisciplinary projects in pathology and biomedical engineering

🏆 Awards & Honors

Published in top journals like PNAS, Bioactive Materials, Nano Today, Coordination Chemistry Reviews. Recognized for groundbreaking work in nano-delivery systems and cancer therapeutics. Received multiple research grants and fellowships for contributions to biomedicine. Acknowledged for excellence in interdisciplinary biomedical research and innovation

🔬 Research Focus

Nanomedicine and cancer immunotherapy. Tumor-targeted drug delivery and nano-biomaterials. Biosynthesized nanoparticles for therapeutic applications. Photothermal PCR and rapid nucleic acid detection. Exploring tumor microenvironment and immune evasion mechanisms

🔹 Conclusion

Maonan Wang is a strong candidate for the Best Researcher Award, given his high-impact publications, interdisciplinary expertise, and contributions to biomedical nanotechnology and cancer therapy. Strengthening his profile with grants, mentorship roles, and translational research impact could further bolster his competitiveness. 🚀

Publication

  • Title: In situ self-assembling Au-DNA complexes for targeted cancer bioimaging and inhibition
    Year: 2020
    Author: Maonan Wang, Yun Chen, Weijuan Cai, Huan Feng, Tianyu Du, Weiwei Liu, Hui Jiang, Alberto Pasquarelli, Yossi Weizmann*, Xuemei Wang*
    Citation: PNAS, 117: 308 (IF=11.1)

 

  • Title: Baiting bacteria with amino acidic and peptidic corona coated defect-engineered antimicrobial nanoclusters for optimized wound healing
    Year: 2024
    Author: Maonan Wang†, Houjuan Zhu†, Yuling Xue, Yanxia Duan, Hua Tian, Qi Liu, Yuzhu Zhang, Zibiao Li, Xian Jun Loh, Enyi Ye, Gang Yin, Xuemei Wang, Xianguang Ding, David Tai Leong*
    Citation: Bioactive Materials, 42: 628-643 (IF=18)

 

  • Title: An ultrafast and portable nucleic acid detection system based on photothermal PCR and real-time fluorescence detection
    Year: 2023
    Author: Liangxi Zhu, Jingzhou Zhao, Yile Fang, Zhukang Guo, Maonan Wang*, Nongyue He*
    Citation: Nano Today, 53: 102019 (IF=13.2)

 

  • Title: Advance of nano anticancer therapies targeted on tumor-associated macrophages
    Year: 2021
    Author: Maonan Wang, Jingzhou Zhao, Hongjie Xiong, Hongbing Lu, Hui Jiang, Xuemei Wang*
    Citation: Coordination Chemistry Reviews, 446: 214126 (IF=20.6)

 

  • Title: Tumor targeted nano-delivery system of therapeutic RNA
    Year: 2022
    Author: Maonan Wang, Jingzhou Zhao, Hui Jiang, Xuemei Wang*
    Citation: Materials Horizons, 9: 1111-1140 (IF=13.3)

 

  • Title: Bio-assembled smart nanocapsules for targeted delivery of KRAS shRNA and cancer cell bioimage
    Year: 2023
    Author: Maonan Wang, Zengchao Guo, Jiayu Zeng, Liu Liu, Yihan Wang, Jinpeng Wang, Hongbing Lu, Haijun Zhang, Hui Jiang, Xuemei Wang*
    Citation: Chinese Chemical Letters, 34: 107651 (IF=9.1)

 

  • Title: In situ biosynthesized gold nanoclusters inhibiting cancer development via the PI3K–AKT signaling Pathway
    Year: 2019
    Author: Maonan Wang†, Zeqian Yu†, Huan Feng, Jianling Wang, Lishan Wang, Yu Zhang, Lihong Yin, Ying Du, Hui Jiang, Xuemei Wang*, Jiahua Zhou*
    Citation: Journal of Materials Chemistry B, 7(35): 5336-5344 (IF=7.57)

 

  • Title: Biophysics involved in the process of tumor immune escape
    Year: 2022
    Author: Maonan Wang, Hui Jiang, Xiaohui Liu*, Xuemei Wang*
    Citation: iScience, 25: 104124 (IF=5.8)

 

  • Title: The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/Hippo signaling pathway
    Year: 2021
    Author: Maonan Wang†, Manli Dai†, Dan Wang†, Ting Tang, Fang Xiong, Bo Xiang, Ming Zhou, Xiaoling Li, Yong Li, Wei Xiong, Guiyuan Li, Zhaoyang Zeng*, Can Guo*
    Citation: Cancer Letters, 512: 60-72 (IF=9.7)

 

  • Title: The regulatory networks of the Hippo signaling pathway
    Year: 2021
    Author: Maonan Wang, Manli Dai, Dan Wang, Wei Xiong, Zhaoyang Zeng*, Can Guo*
    Citation: Journal of Cancer, 12(20): 6216-6230 (IF=3.9)

 

  • Title: Additive Manufacturing in Orthopedics: A Review
    Year: 2022
    Author: Yingchao Zhao, Zhen Wang, Jingzhou Zhao, Mubashir Hussain, Maonan Wang*
    Citation: ACS Biomaterials Science & Engineering, 8(4): 1367-1380 (IF=5.7)

 

Rumeysa Çolak | Oncologyst | Best Researcher Award

Published on by Young Scientists Awards

Dr. Rumeysa Çolak | Oncologyst | Best Researcher Award

Bakırköy Dr.Sadi Konuk Training and Research Hospital ,Turkey 🏆

Dr. Rumeysa Çolak is a dedicated Research Assistant at the Department of Medical Oncology, Training and Research Hospital in Istanbul, Turkey, she graduated from Inonu University Faculty of Medicine in July 2015. Passionate about medical research, Dr. Çolak’s professional interests focus on oncology, internal medicine, and the clinical application of various treatments. She is proficient in English and contributes to the medical community through case presentations, research articles, and poster presentations. Dr. Çolak has participated in multiple scientific events, particularly focusing on novel cancer treatments and the intersection between chronic diseases like diabetes and inflammatory bowel diseases. Her commitment to improving patient outcomes in complex cases has earned her respect in the field.

Profile

Scopus

Education 🎓

Dr. Rumeysa Çolak graduated from the Faculty of Medicine at Inonu University in July 2015, with a strong foundation in medical science. Her dedication to advancing her knowledge and skills led her to further her education, earning her a role as a Research Assistant in 2022 at the Training and Research Hospital’s Medical Oncology Department. Alongside her medical degree, Dr. Çolak achieved a proficiency score of 65 on the YDS (Foreign Language Exam) in 2014, showcasing her ability to work in both Turkish and English-speaking environments. Her focus on oncology and medical research reflects her academic drive and desire to contribute to advancing healthcare in Turkey. Dr. Çolak’s comprehensive training in medical research, patient care, and specialized oncology practices supports her role as a valuable asset to the medical community.

Experience 🏢

Dr. Rumeysa Çolak’s professional journey began with her graduation from Inonu University Faculty of Medicine in 2015. Following her medical degree, she gained experience working in various clinical settings before securing her current position as a Research Assistant in the Medical Oncology Department at a renowned Training and Research Hospital in Istanbul. Since joining in 2022, Dr. Çolak has actively contributed to oncology research and patient care, particularly focusing on treatments for complex conditions such as advanced melanoma and metabolic diseases. She has been involved in scientific events, including case presentations and research articles, further solidifying her role in the medical community. Dr. Çolak’s expertise spans clinical research, patient management, and treatment protocols, with an emphasis on improving patient outcomes in challenging cases, such as liver failure with encephalopathy and inflammatory bowel diseases.

Research Interests 🔬

Dr. Rumeysa Çolak’s research focuses on advancing knowledge in oncology, particularly in the treatment of advanced melanoma and other complex diseases. Her work investigates innovative therapies such as nivolumab in patients with BRAF mutant advanced melanoma. In addition to her focus on oncology, Dr. Çolak’s research spans areas like inflammatory bowel diseases (IBD), examining the prevalence of irritable bowel syndrome-like symptoms in patients with inactive IBD and their impact on quality of life. She is also interested in diabetes and its comorbidities, having researched the use of statins in Type 2 diabetes patients. Through her research, Dr. Çolak aims to contribute to understanding the molecular mechanisms of diseases, the impact of treatments on patient outcomes, and ways to improve quality of life for patients with chronic conditions. Her ongoing work holds promise for the development of new strategies for managing complex medical conditions.

Awards 🏅

Dr. Rumeysa Çolak has been recognized for her dedication and contributions to medical research and clinical practice. Throughout her academic and professional journey, she has participated in several prestigious scientific events and conferences. One notable achievement includes her involvement in the 55th National Diabetes Metabolism and Nutritional Diseases Congress in Cyprus, where she presented a poster on statin use in Type 2 diabetes mellitus patients. Additionally, Dr. Çolak’s research articles and case presentations have garnered attention in the medical community, contributing to the understanding of complex conditions like irritable bowel syndrome and melanoma treatment. While she has not yet received specific awards, Dr. Çolak’s commitment to advancing healthcare and her proactive involvement in scientific research position her as a rising star in the field of oncology and internal medicine.

Publications 📚

1. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

2. ‘Statin Use and Objectives of The Target in Type 2 Diabetes Mellitus Patients: Is The Resistant in The Patient or The Physician?’

3. ‘Mutation in Complement Regulating Genes in Patients With Thrombotic Microangiopathic Resistant to Plasmapheresis Treatment’

4. ‘Assessment of Disease Activity by Fecal Occult Blood Test in Inflammatory Bowel Disease’

5. ‘Prevalence of Irritable Bowel Syndrome Like Symptoms in Patients With Inactive Inflammatory Bowel Disease and Relation With Quality of Life’

6. ‘A Case of Aggressive Prolactinoma’s Masked by HOOK Effect in Postmenopausal Period’

7. ‘Liver Transplantation Data of 20 Years Experience of Dokuz Eylul University Faculty of Medicine’

8. ‘Rare Gastric Metastasis of Breast Cancer’

Conclusion 🏅

Dr. Rumeysa Çolak is an excellent candidate for the “Best Researcher Award” given her diverse research portfolio, proven expertise, and significant impact in her field. She has demonstrated remarkable dedication to advancing both scientific knowledge and practical applications in oncology and chronic disease management. Her ongoing contributions to medical research and her ability to address complex health issues through innovative approaches underscore her suitability for such a prestigious recognition. Therefore, Dr. Çolak’s work makes her a strong contender for this award, and she deserves recognition for her excellence in research.

 

 

 

 

 

EVANKA MADAN | Cancer Biology | Best Researcher Award

Published on by Young Scientists Awards

Dr EVANKA MADAN | Cancer Biology | Best Researcher Award

Dr EVANKA MADAN, Sir Ganga Ram Hospital, India

Dr. Evanka Madan is a distinguished Consultant and Assistant Professor at Sir Ganga Ram Hospital, New Delhi, India. With a robust background in biochemistry and molecular biology, she has achieved significant acclaim in her field. Her research spans drug discovery for parasitic diseases, focusing on Leishmania and malaria. Dr. Madan has been recognized with numerous awards, including the Young Scientist Fellowship by ICMR-DHR and the Best Young Researcher Award at the Science Conclave cum NBRCOM. She has also made substantial contributions through international collaborations, including research stints at Albert Einstein College of Medicine, New York. Dr. Madan’s work has been featured in prominent journals, reflecting her commitment to advancing biomedical research and therapy.

Publication Profile

Scopus

Strengths for the Award

  1. Research Excellence: Dr. Madan’s research has significantly advanced our understanding of diseases like Leishmania and cardiovascular issues. Her work on identifying novel drug targets and mechanisms in infectious diseases and cancer demonstrates her high-impact research capabilities.
  2. Recognition and Awards: Dr. Madan has received numerous accolades, including the Young Scientist Fellowship from ICMR-DHR and several Best Paper and Poster Awards. This recognition underscores her contributions to the field and her potential for community impact.
  3. International Experience: Her research experience spans prestigious institutions globally, including Albert Einstein College of Medicine, and she has been involved in international conferences, enhancing her visibility and collaborative opportunities.
  4. Public Engagement: Dr. Madan has delivered public scientific lectures and talks at international conferences, demonstrating her commitment to communicating scientific knowledge to the broader community.
  5. Technical Proficiency: Her expertise in both molecular and computational biology equips her to address complex biological questions, further strengthening her research’s potential for community impact.

Areas for Improvement

  1. Community Outreach: While Dr. Madan’s research is highly specialized, further engagement with community-based projects and local health initiatives could amplify the direct benefits of her work to the general public.
  2. Application of Research Findings: Emphasizing how her research findings are translated into practical applications or interventions that directly benefit community health would strengthen her candidacy. Demonstrating more concrete examples of her research’s impact on public health policies or local health practices could be beneficial.
  3. Interdisciplinary Collaborations: Expanding collaborations beyond her immediate field could offer new perspectives and enhance the applicability of her research findings. Collaborations with social scientists or public health experts might enhance the community relevance of her work.

Education

Dr. Evanka Madan earned her PhD in Biochemistry from the All India Institute of Medical Sciences (AIIMS), New Delhi, in 2015. She completed her MSc in Medical Biotechnology from the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, in 2010, where she was the top-ranked student. Her undergraduate studies in Biological Sciences were completed at Sri Venkateshwara College, Delhi University, in 2008, securing third position. Her academic foundation is further supported by her early education at Delhi Public School, where she excelled in the CBSE curriculum.

Experience

Dr. Madan has extensive experience in biochemistry and molecular biology. As a Senior Scientist at Dhiti Life Sciences, she focused on recombinant antigens and monoclonal antibodies. Her role as a CSIR Scientist Pool Officer at Jawaharlal Nehru University involved investigating druggable targets in Leishmania. Previous roles include a Postdoctoral Fellowship at JNU, Research Associate positions at NII and IGIB, and a PhD tenure at AIIMS. Her research encompasses host-pathogen interactions, molecular characterization, and drug discovery, underscoring her expertise in parasitology and cancer biology.

Awards and Honors

Dr. Madan’s accolades include the prestigious Young Scientist Fellowship by ICMR-DHR (2021-24) and the Best Young Researcher Award at the Science Conclave cum NBRCOM, 2023. She has received multiple best presentation and poster awards at international conferences, such as the ICID Conference in Sydney and the National Congress of Parasitology. Additionally, she has been honored with travel grants from CSIR, ICMR, and DST for global conferences, highlighting her contributions to research and science communication.

Research Focus

Dr. Madan’s research primarily focuses on parasitic diseases, particularly Leishmania and malaria. Her work involves the molecular characterization of pathogen-host interactions, drug target identification, and pre-clinical evaluations. Recent studies explore the role of sphingosine kinase in Leishmania and the impact of arginine sensing in host-pathogen dynamics. Dr. Madan’s research also extends to cancer biology, with investigations into the FAT1 gene’s role in glioma and its influence on tumor biology and inflammation.

Publication Top Notes

Identification of a De Novo Peptide against Palmitoyl Acyltransferase 6 to Block Survivability and Infectivity of Leishmania donovani 🦠🔬

Screening of Traditional Medicinal Plant Extracts and Compounds Identifies a Potent Anti-Leishmanial Diarylheptanoid from Siphonochilus aethiopicus 🌿🦠

Targeting an Essential Plasmodium Cold Shock Protein to Block Growth and Transmission of Malaria Parasite 🦠💉

Cuscuta reflexa Possess Potent Inhibitory Activity Against Human Malaria Parasite: An In Vitro and In Vivo Study 🌿🦠

Host-Erythrocytic Sphingosine-1-Phosphate Regulates Plasmodium Histone Deacetylase Activity and Exhibits Epigenetic Control over Cell Death and Differentiation 🦠🧬

Rapid Diagnosis of Plasmodium falciparum Malaria Using a Point-of-Care Loop-Mediated Isothermal Amplification Device 🦠🔬

Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and Promotes Leishmania donovani Survival 🦠🔬

Chromatin-Remodeling Factor BRG1 Is a Negative Modulator of L. donovani in IFNγ Stimulated and Infected THP-1 Cells 🦠🔬

Conclusion

Dr. Evanka Madan’s extensive research achievements, recognition in the field, and international experience position her as a strong candidate for the Research for Community Impact Award. Her work addresses critical health issues, and her expertise has the potential to significantly benefit community health. By enhancing her focus on community engagement and translating research into practical health solutions, she could further strengthen her impact. Overall, Dr. Madan’s contributions make her a commendable candidate for this award.